ESLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLAW

Estrella Immunopharma, Inc.

Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.38−0.05 (-11.65%)

Close on Oct 19, 2026

Market cap: $16.17M
P/E (TTM): –
Dividend yield: –

Estrella Immunopharma, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2024 2024-06-30	FY 2021 2021-12-31
Research & Development	4.11	–
General & Administrative	3.20	–
Operating Expenses	7.31	–
Operating Income	-7.31	-0.25
Interest & Investment Income	–	0.00
Gain (Loss) on Investments	–	0.00
Pretax Income	-7.31	-0.25
Income Tax Expense	0.00	0
Net Income incl. Noncontrolling Interests	–	-0.25
Net Income	-7.31	-0.25
EPS (Basic)(per share)	-0.27	–
EPS (Diluted)(per share)	-0.27	–
Shares Outstanding (Basic, Weighted)(shares)	27	1.18
Shares Outstanding (Diluted, Weighted)(shares)	27	1.18

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2024: -447.6%

Financial strength

Current ratio: 0.20
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1.1%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –